Xenetic Biosciences Stock Price - XBIO

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
After Hours
Last Trade
Last $ 1.18 ▲ 0.04 (3.51%)
Company Name Stock Ticker Symbol Market Type
Xenetic Biosciences Inc XBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.03 2.7% 1.14 1.17 1.0452 1.08 1.11 18:00:00
Bid Price Ask Price Spread Spread % News
1.10 1.17 0.07 5.98% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
511 160,678 $ 1.12 $ 179,984 949,177 0.51 - 15.25
Last Trade Time Type Quantity Stock Price Currency
17:50:03 50 $ 1.16 USD

Xenetic Biosciences Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 6.42M 5.63M $ -7.30M -9.62 - 5.23M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 1.00 12.20%

more financials information »

Xenetic Biosciences News

Loading Messages....

Latest XBIO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XBIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.191.210.931.10296,221-0.05-4.2%
1 Month1.431.570.931.28423,362-0.29-20.28%
3 Months1.801.960.931.36638,558-0.66-36.67%
6 Months0.8415.250.511.95467,8580.3035.71%
1 Year2.8215.250.511.96274,930-1.68-59.57%
3 Years3.7515.250.513.08176,167-2.61-69.6%
5 Years0.2515.250.1752.84126,2380.89356.0%

Xenetic Biosciences Description

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.


Your Recent History
NASDAQ
XBIO
Xenetic Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.